Jansen, S., Chan, N., de Borst, G. J., Hinchliffe, R., Vemulapalli, S., Teraa, M., & LEADER-PAD Study Group. (2025). Low Dose Colchicine in Patients with Peripheral Artery Disease to Address Residual Vascular Risk (LEADER-PAD) Trial: Relevance and Importance of a Global Initiative. Eur J Vasc Endovasc Surg, 70(3), 401–402. https://doi.org/10.1016/j.ejvs.2025.05.004

Jansen, Shirley, Noel Chan, Gert J. de Borst, Robert Hinchliffe, Sreekanth Vemulapalli, Martin Teraa, and LEADER-PAD Study Group. “Low Dose Colchicine in Patients with Peripheral Artery Disease to Address Residual Vascular Risk (LEADER-PAD) Trial: Relevance and Importance of a Global Initiative.” Eur J Vasc Endovasc Surg 70, no. 3 (September 2025): 401–2. https://doi.org/10.1016/j.ejvs.2025.05.004.

Jansen S, Chan N, de Borst GJ, Hinchliffe R, Vemulapalli S, Teraa M, et al. Low Dose Colchicine in Patients with Peripheral Artery Disease to Address Residual Vascular Risk (LEADER-PAD) Trial: Relevance and Importance of a Global Initiative. Eur J Vasc Endovasc Surg. 2025 Sep;70(3):401–2.

Jansen, Shirley, et al. “Low Dose Colchicine in Patients with Peripheral Artery Disease to Address Residual Vascular Risk (LEADER-PAD) Trial: Relevance and Importance of a Global Initiative.” Eur J Vasc Endovasc Surg, vol. 70, no. 3, Sept. 2025, pp. 401–02. Pubmed, doi:10.1016/j.ejvs.2025.05.004.

Jansen S, Chan N, de Borst GJ, Hinchliffe R, Vemulapalli S, Teraa M, LEADER-PAD Study Group. Low Dose Colchicine in Patients with Peripheral Artery Disease to Address Residual Vascular Risk (LEADER-PAD) Trial: Relevance and Importance of a Global Initiative. Eur J Vasc Endovasc Surg. 2025 Sep;70(3):401–402.